<SEC-DOCUMENT>0001558370-23-009508.txt : 20230512
<SEC-HEADER>0001558370-23-009508.hdr.sgml : 20230512
<ACCEPTANCE-DATETIME>20230512080213
ACCESSION NUMBER:		0001558370-23-009508
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20230512
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230512
DATE AS OF CHANGE:		20230512

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Gain Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001819411
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				851726310
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40237
		FILM NUMBER:		23913225

	BUSINESS ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
		BUSINESS PHONE:		(301) 500-1556

	MAIL ADDRESS:	
		STREET 1:		4800 HAMPDEN LANE
		STREET 2:		SUITE 200
		CITY:			BETHESDA
		STATE:			MD
		ZIP:			20814
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ganx-20230512x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.5.9 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 5/11/2023 8:35:03 PM -->
      <!-- iXBRL Library version: 1.0.8476.13996 -->
      <!-- iXBRL Service Job ID: f029d826-7cb9-48c4-9726-770eb7ab97dd -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ganx="http://www.gaintherapeutics.com/20230512" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityCentralIndexKey" id="Tc_r9b28diRhUCZdrmueyAOSA_2_1">0001819411</ix:nonNumeric><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:AmendmentFlag" id="Tc_g2TEygbZiEGq9pmgyYK1JA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="ganx-20230512.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001819411</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-05-12</xbrli:startDate><xbrli:endDate>2023-05-12</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_aa5a70af_7da3_4674_b0bd_fe24cd3c18fd"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:11pt;font-weight:bold;">_______________</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:DocumentType" id="Narr_q21PL-xFj0eNBqHKheZsiQ"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Pursuant to Section 13 or 15(d) of the</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 18pt 0pt;"><b style="font-weight:bold;">Date of report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_xrLhIzdafkKBoSZi0jeODQ"><b style="font-weight:bold;">May 12, 2023</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityRegistrantName" id="Narr_A7B81zAdWU6R1AZPkb17mA"><b style="font-weight:bold;">Gain Therapeutics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Exact Name of the Registrant as Specified in Charter)</p><a id="_5a6150d6_aac7_4862_a194_71d094488f8b"></a><a id="Tc_iizY9H_WUU-r0ulMX6gdzw_2_0"></a><a id="Tc_7M31kz-q1kitLAnEnREp5w_2_2"></a><a id="Tc_2pTfweftN0KBq6AJCpMCpg_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.15%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:35.83%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:26.53%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:34.79%;margin:0pt;padding:1.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:35.83%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_B4bojGnm5USAYq6Pk1bVDA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:1.5pt;"></td><td style="vertical-align:bottom;width:26.53%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityFileNumber" id="Tc_x6YoD16kUECeyYk2v_xM4g_1_2"><b style="font-size:9pt;font-weight:bold;">001-40237</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:1.5pt;"></td><td style="vertical-align:bottom;width:34.79%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityTaxIdentificationNumber" id="Tc_MA4FTymF5E6sOPrRaBTYbg_1_4"><b style="font-size:9pt;font-weight:bold;">85-1726310</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:35.83%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(State or Other Jurisdiction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">of Incorporation)</b></p></td><td style="vertical-align:bottom;width:1.42%;margin:0pt;padding:1.5pt;"></td><td style="vertical-align:bottom;width:26.53%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br /><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:bottom;width:1.4%;margin:0pt;padding:1.5pt;"></td><td style="vertical-align:bottom;width:34.79%;margin:0pt;padding:1.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityAddressAddressLine1" id="Narr_WrkgAjYpF0Ch0UkVXCkuAg"><b style="font-size:9pt;font-weight:bold;">4800 Montgomery Lane</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityAddressAddressLine2" id="Narr_gforBLbCAkudwPIeAdgM3w"><b style="font-size:9pt;font-weight:bold;">Suite 220</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityAddressCityOrTown" id="Narr_0EgY526XO0WRUL3LNceJeA"><b style="font-size:9pt;font-weight:bold;">Bethesda</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_PLfEiokbh0ezNVXhGiY7PA"><b style="font-size:9pt;font-weight:bold;">Maryland</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:EntityAddressPostalZipCode" id="Narr_YplD6_TT50eeHM5EIdX8Zw"><b style="font-size:9pt;font-weight:bold;">20814</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(<span style="font-size:10pt;">Address of principal executive offices) </span>(Zip Code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:CityAreaCode" id="Narr_2F5DroE9F0yvloXpUrFvhA"><b style="font-size:9pt;font-weight:bold;">301</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:LocalPhoneNumber" id="Narr_r9VhBCUAEUmASXM3mUM_1w"><b style="font-size:9pt;font-weight:bold;">500-1556</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Registrant&#8217;s telephone number, including area code)</p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_zIOwwPPyfUCkOWxeMsrS4Q"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_3I9ar1BM60q4qOjVGS0Gvw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_jk2st6kjikKK716_up3kAA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:18pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_0uN6J9KST0izMdjCvtqvCA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;font-style:normal;font-weight:normal;">&#9744;</span></ix:nonNumeric></span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 12pt 0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><a id="_7cd6c8e4_2c28_4698_834e_0a15231457ee"></a><div style="margin-left:-0.4pt;"><a id="Tc_dHDcAiEiFESVZYRMevUozQ_1_0"></a><a id="Tc_-N7bCjtwt0CMIonWLGEzxA_1_1"></a><a id="Tc_dSgqkhjlkkCHdm5UZlrwgQ_1_2"></a><a id="Tc_hAgnaPdzK0yGVUPPFLZlOg_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:99.21%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:36.57%;margin:0pt;padding:1.5pt 1.1pt 1.5pt 1.1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:27.02%;margin:0pt;padding:1.5pt 1.1pt 1.5pt 1.1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:36.4%;margin:0pt;padding:1.5pt 1.1pt 1.5pt 1.1pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:36.57%;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:bottom;width:27.02%;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Trading symbol(s)</b></p></td><td style="vertical-align:bottom;width:36.4%;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="color:#212529;font-weight:bold;">Name of exchange on which registered</b></p></td></tr><tr><td style="vertical-align:bottom;width:36.57%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:Security12bTitle" id="Tc_PkMIrn85TkWdzDdiN4I59Q_2_0"><span style="color:#212529;font-size:9pt;">Common Stock, $0.0001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:27.02%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" name="dei:TradingSymbol" id="Tc_NbWnnL5r-0CWapKyu8YDfQ_2_1"><span style="color:#212529;font-size:9pt;">GANX</span></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:36.4%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:1.5pt 0.72pt 1.5pt 0.72pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="color:#212529;font-size:9pt;">The </span><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_OY2pAh-B9kag5Ar1yOihNw"><span style="color:#212529;font-size:9pt;">NASDAQ</span></ix:nonNumeric><span style="color:#212529;font-size:9pt;"> Stock Market LLC</span></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 6pt 0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_N3OMtQnZP0-zCcDVExMZtw"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><ix:nonNumeric contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_eR5MHPZ1Ik-409s2e3V-Tg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><a id="_3f609311_6f21_46d2_9b9d_22d8696268f2"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 2.02 Results of Operations.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On May 12, 2023, Gain Therapeutics, Inc. (the &#8220;Company&#8221;) issued a press release announcing its financial results for the first quarter ended March 31, 2023, and business update. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included or incorporated in this Item 2.02, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information and exhibit be deemed incorporated by reference into any of the Company&#8217;s filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Item 9.01. Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">(d) <span style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibits</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">The exhibits listed below are furnished as part of this Current Report on Form 8-K.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:98.57%;"><tr style="height:1pt;"><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:86.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:justify;border-bottom:1px solid #000000;margin:0pt 5.5pt 0pt 4pt;"><b style="font-weight:bold;">Exhibit No.</b></p></td><td style="vertical-align:top;width:86.89%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-bottom:1pt;text-align:center;border-bottom:1px solid #000000;margin:0pt 5.2pt 0pt 2.5pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.5pt 0pt 4pt;">99.1</p></td><td colspan="2" style="vertical-align:top;width:87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.2pt 0pt 2.5pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="ganx-20230512xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Gain Therapeutics, Inc. Press Release dated May 12, 2023.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.99%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.5pt 0pt 4pt;">104</p></td><td colspan="2" style="vertical-align:top;width:87%;margin:0pt;padding:0pt 0.5pt 0pt 0.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 5.2pt 0pt 2.5pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.5pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 1.64pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_06636757_6f03_4f0f_825b_3e50753aa186"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SIGNATURE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:25.2pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td colspan="2" style="vertical-align:top;width:47.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:51.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GAIN THERAPEUTICS, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"></td><td colspan="3" style="vertical-align:top;width:51.77%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: May 12, 2023</p></td><td style="vertical-align:top;width:4.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td colspan="2" style="vertical-align:top;width:47.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ C. Evan Ballantyne</p></td></tr><tr><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">C. Evan Ballantyne</p></td></tr><tr><td style="vertical-align:top;width:48.22%;margin:0pt;padding:0pt;"></td><td colspan="2" style="vertical-align:top;width:7.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:44.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 4.55pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.09pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ganx-20230512xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 5/11/2023 08:35:02 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 6pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Exhibit 99.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">GAIN THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATE</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson&#8217;s disease</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Company is on track to submit application for start of Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Received a $2.8 million (CHF $2.5 million) grant from Innosuisse, the Swiss Innovation Agency, to advance the development of GT-02287 in GBA1 Parkinson&#8217;s disease</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Obtained a grant in the aggregate amount of $1.3 million (EUR 1.2 million) to a consortium led by Gain Therapeutics for further development of the Company&#8217;s novel small molecule allosteric regulators against Alpha-1 Antitrypsin Deficiency</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Appointed C. Evan Ballantyne as Chief Financial Officer in April</i></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">BETHESDA, MD, May&#160;12, 2023</b>&#160;-- Gain Therapeutics,&#160;Inc. (Nasdaq: GANX) (&#8220;Gain&#8221;, or the &#8220;Company&#8221;), a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced financial results for the first quarter ended March&#160;31, 2023, and highlighted recent corporate progress.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">&#8220;We are pleased with the progress we have made this&#160;year and look forward to advancing our lead candidate GT-02287 for the treatment of GBA1 Parkinson&#8217;s disease into the clinic later this&#160;year,&#8221; said Matthias Alder, Chief Executive Officer. &#8220;In addition, the grants obtained for the development of GT-02287 and our AAT research program provide significant non-dilutive capital and validate the potential of Gain&#8217;s allosteric protein regulators as small molecule therapies in a broad range of diseases. Further, we are thrilled that Evan Ballantyne joined us last&#160;month as our new Chief Financial Officer to support the continued growth of Gain at this important inflection point when we are poised to become a clinical stage biotech company.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Pipeline Highlights</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson&#8217;s disease.</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;"> With the completion of GLP-toxicology studies, Gain remains on track to submit the application for the initiation of a Phase 1 clinical trial of GT-02287 to the Human Research Ethics Committee (HREC) in Australia in mid-2023. The Phase 1 clinical trial is expected to commence in the second half of 2023 and will evaluate administration of both single and multiple ascending dose levels of GT-02287 in healthy volunteers to assess safety and pharmacokinetics.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Presented positive preclinical data supporting disease-modifying potential of allosteric GCase regulators for the treatment of Alzheimer&#8217;s disease at the AD/PD conference in Gothenburg, Sweden. </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">In March, Gain presented new preclinical data at the 2023 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases and related neurological disorders (AD/PD) in a poster presentation titled: &#8220;</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;">Small-Molecule Structurally Targeted Allosteric Regulators of Glucocerebrosidase Show Neuroprotective Properties in Cell-Based Models of Alzheimer&#8217;s Disease</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">.&#8221; The data generated in two cell-based assays of Alzheimer&#8217;s disease </font></td></tr></table></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">1</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">showed that Gain&#8217;s orally bioavailable, brain-penetrant allosteric regulators of GCase show promising activity against Amyloid Beta 1-42 (A&#946;-1-42) and oligomeric Tau toxicity, which are thought to underlie neurodegeneration and cognitive impairment in Alzheimer&#8217;s disease, supporting their potential as a disease-modifying, novel pharmacological option for the treatment of AD and other tauopathies.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recent Corporate Updates</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Appointed C. Evan Ballantyne as Chief Financial Officer in April&#160;2023. </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Mr.&#160;Ballantyne brings over 20&#160;years of experience managing the financing and corporate strategy of publicly traded and private companies in the healthcare industry.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Received a $2.8 million (CHF 2.5 million) grant to advance lead program in GBA1 Parkinson&#8217;s disease. </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">The funding provided by Innosuisse, the Swiss Innovation Agency, as part of its Swiss Accelerator program to Gain&#8217;s Swiss subsidiary GT Gain Therapeutics SA, will support clinical pharmacology and preclinical studies with Gain&#8217;s drug candidate GT-02287, which are required to be performed as Gain&#8217;s lead program for the treatment of GBA1 Parkinson&#8217;s disease progresses through Phase 1 and Phase 2 clinical studies.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">Obtained a grant in the aggregate amount of $1.3 million (EUR 1.2 million) to a consortium led by Gain Therapeutics for AAT research program. </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">The grant awarded to the consortium will support a research project conducted by Gain Therapeutics, the Institute for Research in Biomedicine, Newcells Biotech and the University of Helsinki to develop the Company&#8217;s novel small molecule allosteric regulators against Alpha-1 Antitrypsin (AAT) Deficiency, a rare genetic condition that can result in serious lung and liver diseases.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Financial Results:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Research and development (R&amp;D) expenses totaled $2.8 million for the three&#160;months ended March&#160;31, 2023, as compared to $1.6 million for the same period in 2022. The $1.2 million increase in R&amp;D expense for the three&#160;months ended March&#160;31, 2023 was primarily due to increases in costs associated with pre-IND clinical studies, quality and clinical manufacturing as Gain&#8217;s GBA1 Parkinson&#8217;s disease program advances toward clinical trials. The increase in R&amp;D expenses was also due to higher personnel-related costs associated with an increase in employee headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">General and administrative (G&amp;A) expenses totaled $2.5 million for the three&#160;months ended March&#160;31, 2023, as compared to $1.8 million for the same period in 2022. The increase in G&amp;A expenses of $0.7 million for the three&#160;months ended March&#160;31, 2023 was primarily due to higher legal fees, accounting, insurance, and information technology costs. The increase in G&amp;A expenses was also due to an increase in personnel-related costs resulting from an increase in employee headcount.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Net loss for the three-month period ended March&#160;31, 2023, was $5.1 million, or $0.43 per share basic and diluted, compared to a net loss of $3.3 million, or $0.28 per share basic and diluted, for the same period in 2022. The net loss includes non-cash stock-based compensation expenses in the amount of $0.6 million and $0.3 million for the three-month periods ended March&#160;31, 2023 and 2022, respectively.</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash, cash equivalents and marketable securities were $18.8 million as of March&#160;31, 2023. The Company believes that this amount, together with the proposed research grant funding detailed above and ATM proceeds received in April&#160;2023, will be sufficient to support current operations into the third quarter of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">GAIN THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three&#160;Months Ended March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Revenues:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Collaboration revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 55,180</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 37,538</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;-</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 7,468</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total revenues</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 55,180</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 45,006</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,791,205)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,556,440)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (2,493,759)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,777,043)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,284,964)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,333,483)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,229,784)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,288,477)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income (expense):</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Interest income/(expense), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 152,035</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,651)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Foreign exchange gain/(loss), net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (42,842)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 19,162</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss before income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,120,591)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,270,966)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (16,728)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (1,677)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,137,319)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (3,272,643)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per shares:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per share attributable to common stockholders&#160;- basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.43)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (0.28)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:69.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average common shares&#160;- basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 11,935,081</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 11,883,368</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">GAIN THERAPEUTICS,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 6pt 0pt;">CONDENSED CONSOLIDATED BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">March&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">5,988,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 7,311,611</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities&#160;&#8211; current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">11,827,528</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 12,826,954</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">137,383</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 103,877</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">1,368,871</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 848,854</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 19,321,984</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 21,091,296</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Marketable securities&#160;- non current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 988,388</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,941,488</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 144,636</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 144,379</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Internal-use software</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 208,913</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 213,967</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease&#160;- right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 609,877</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 659,933</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 31,122</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 30,818</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Long-term deposits and other non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 17,655</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 17,506</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 2,000,591</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 3,008,091</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 21,322,575</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 24,099,387</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and stockholders&#8217; equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 2,213,489</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,626,100</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability&#160;&#8211; current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 232,507</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 229,080</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">2,599,763</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 2,106,756</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Deferred income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 55,180</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans&#160;&#8211; current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 109,200</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 108,135</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 5,154,959</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 4,125,251</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Defined benefit pension plan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 164,568</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 157,580</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liability&#160;- non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 385,922</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 441,784</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loans&#160;- non-current</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 478,296</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 495,258</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total non-current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,028,786</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,094,622</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 6,183,745</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 5,219,873</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; nil shares issued and outstanding as of March&#160;31, 2023 and December&#160;31, 2022.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#8212;</p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Common stock, $0.0001 par value: 50,000,000 shares authorized; 12,087,142 issued and outstanding as of March&#160;31, 2023; 11,883,368 issued and outstanding as of December&#160;31, 2022.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,209</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 1,189</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 58,694,827</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 57,358,895</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 96,310</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 35,627</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (38,516,197)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (20,925,459)</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Loss for the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (5,137,319)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> (17,590,738)</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 15,138,830</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 18,879,514</font></p></td></tr><tr><td style="vertical-align:top;width:70.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.07%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 21,322,575</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.1%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="white-space:pre-wrap;"> 24,099,387</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">About Gain Therapeutics,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Gain Therapeutics,&#160;Inc. is a biotechnology company leading the discovery and development of allosteric small molecule therapies. With its proprietary computational discovery platform SEE-Tx&#174;, Gain Therapeutics is transforming drug discovery by identifying novel allosteric targets on proteins involved in diseases across the full spectrum of therapeutic areas. By binding to allosteric binding sites, the small molecules discovered with SEE-Tx provide opportunities for a range of drug-protein interactions, including protein stabilization, protein destabilization, targeted protein degradation, allosteric inhibition, and allosteric activation. Gain&#8217;s pipeline spans neurodegenerative diseases, lysosomal storage disorders (LSDs), metabolic disorders, as well as other diseases that can be targeted through protein degradation, such as oncology. Gain&#8217;s lead program in Parkinson&#8217;s disease has been awarded funding support from The Michael J. Fox Foundation for Parkinson&#8217;s Research (MJFF) and The Silverstein Foundation for Parkinson&#8217;s with GBA, the Eurostars-2 joint program with co-funding from the European Union Horizon 2020 research and Innosuisse, and through a Swiss Accelerator Innovation Project supported by Innosuisse. For more information, please visit https://www.gaintherapeutics.com</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cautionary Note&#160;Regarding Forward-Looking Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">This press release contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are &#8220;forward-looking statements. In some cases, you can identify these statements by forward-looking words such as &quot;may,&quot; &quot;might,&quot; &quot;will,&quot; &quot;should,&quot; &quot;expect,&quot; &quot;plan,&quot; &quot;anticipate,&quot; &quot;believe,&quot; &quot;estimate,&quot; &quot;predict,&quot; &quot;goal, &quot; &quot;intend,&quot; &quot;seek, &quot; &quot;potential&quot; or &quot;continue,&quot; the negative of these terms and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the Company&#8217;s growth and upcoming inflection points; the development of the Company&#8217;s current or future product candidates including GT-02287; expectations regarding timing for reporting data from ongoing preclinical studies or the initiation of future clinical trials, including the timing for submission of the application for the initiation of the Phase 1 clinical trial of GT-02287 in Australia and the timing for commencement of such clinical trial; and the Company&#8217;s anticipated cash runway guidance. These forward-looking statements are based on the Company&#8217;s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause the Company&#8217;s preclinical and future clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. These statements are not historical facts but instead represent the Company&#8217;s belief regarding future results, many of which, by their nature, are inherently uncertain and outside the Company&#8217;s control. Many factors may cause differences between current expectations and actual results, including the impacts of the COVID-19 pandemic and other global and macroeconomic conditions on the Company&#8217;s business; clinical trials and financial position; unexpected safety or efficacy data observed during preclinical studies or clinical trials, clinical trial site activation or enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company&#8217;s actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified in the </i></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:always;width:79.3%;border-width:0;"><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 24pt 0pt;"><img src="ganx-20230512xex99d1002.jpg" alt="Graphic" style="display:inline-block;height:41.99pt;left:0%;padding-bottom:0.05pt;position:relative;top:0pt;width:86.49pt;"></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">section titled &#8220;Risk Factors,&#8221; in the Company&#8217;s Annual Report on Form&#160;10-K filed with the Securities and Exchange Commission on March&#160;23, 2023 and its other documents subsequently filed with or furnished to the Securities and Exchange Commission from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Investor&#160;&amp; Media Contact:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><font style="display:inline-block;visibility:hidden;width:0pt;">&#8203;</font><br>Argot Partners</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;">(212) 600-1902</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 12pt 0pt;">Gain@argotpartners.com</p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:27.35pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ganx-20230512xex99d1002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ganx-20230512xex99d1002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !4 *T# 2(  A$! Q$!_\0
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MZV8_]&I2I_''U0\3_ GZ/\CYM_86_:&\0ZCXK7X?^(KZ75;*X@>33;BY;?+
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MLEC"PD6RD_UDQ'(##^%?4'D],5].44HU7"+C'J77R^GB:\:U9W4=ET^8@ 4
M 8 I:**Q/4"O*_VA_ 9\8>#!=VT)EU#36\V-47+/&<!U'Z'_ (#7JE%7&3A)
M21SXBA'$TI4I[,^4O@!/J_@KQLD-SI]Y%IVHJ+>8M X56_@8\=CQ]&->]?&.
MUEOOAGK\$,;RRO  J(I8GYUZ 5V6*6M)U.::G8X,-@'A\-+#.=T[]-KGR-\!
M_#&HZ;\4=(N+C3[J")1-F22%E49B8=2*^N.U%+4U:GM'<UP&"6!I.DI7N[_D
M?"^O^#M6D\2:A(NEWC(UU(P86[D$;S[5]QVHQ;1 \?(/Y5)BEJJM7VEM-C'
M9<L"YM2OS6Z>O^84445@>P9?B3PWI_BS1[C3-3MUN;2<893U![,#V([&OG2+
MX0ZGX!UO4K9(9;ZQFV/;7,49;<HW<,!T89&:^GZ2M85'#1;'FXK TL4XS>DE
MU_0\AE_:J^'\ 4R7M_&&.U=VFS#)]!\M=AX#^*>@_$C[=_8LES)]CV>;]HM9
M(<;LXQN S]T]*XC]IC_D'^!/^QILO_9J]C?[C?C3DH<J:6Y5&5=UI0G)-1MT
MMO\ -F+X,\:Z5X]T-=6T>9Y[)I'B#O&4.Y#AN#SUI-"\;:5XCUS6])L9GDO=
M&E2*\1HRH1F!(P3P>AZ5\\_ +Q)\0M-^'<<'A[P=8ZQI@O+DK=SZFL#,QD.X
M;#TP>*ZS]GFZU*]^(GQ3GUBQCTW4GO;4SVL4PE6-MC\!QUXQ^=7*DH\WE_F8
M4<;*K[)6UEOHTMF]&=1K'[27@/0]8O\ 2[O4[E;RRF:WG2.QF<*ZG!&0I!Y%
M=3X6^)&A>,O#EWKFEW,LNG6K.LLDEN\9!10S?*P!/!'2O#/AUXC\6Z+X\^)R
M>'/"">)('U^5I97U&.V\ILM@88'/'>O;9[_4]3^&^H7.LZ6-&U)[&X\VQ6=9
MQ'A7 ^=>#D8/XTIPC&R7Y_H5AL14JWE)]].5K9VWO9G(P_M4?#B783K4\<;$
M#S9+"<(.V2=E>J6-];ZG9P7=I,EQ;3H)(IHF#*ZD9!!'4$5\I>#_ ([:%HGP
M'L/#][X<UF_=K)[(.]D/L<TCLX5?,+8QD]<=C7N/P5\.WOPZ^$&CZ?KTHBN;
M.WDFN S9$"EF?:3_ +(./P-.I34%IIJ3A,7.M)*335KNR:L^SU?](W)_B3X?
MM_'<'@][X#7IX#<);[#@K@G&[IG )QUQ6MX@UZR\,:)>ZMJ$IAL;.)IYI I8
MJ@&2<#DU\=W7CG0M0T?4_B&-9LD\:#Q"FIVEBSXG^QQGRE@_%"21WP*^COBW
MJMMKOP(\2:C9N);6[T:2>)QW1H\@_D:)4N5Q04<:ZL*CTNE=>FMK^>FI6MOV
MD_ -Q);!]5N+2*X8+'<7=A/%"2>F79-H!]2<5U_C3QYHO@#0?[9UJZ-OI^](
M_-CC:7);[N H)YKYWU/XI1^-/@=9^#-+\(>(M2U6YTNWLH7DT\BWWA5'F!\]
M!C(/TZ5T?QLT>_\ "W[._AK3;H_;-2L;C3H7&_AY%XV[O3(QFJ=*/,EMJ91Q
MM1TYR33M&][.U^V^IV^D?M(>!=<U6STZTU&Z>ZNY5@B5M/G4%F. "2F!R>IK
MLK[QGI>G>+-,\.3RNNJ:C%)-;QB,E65!ELMT'3O7,>%_%_C[4]=M;;6/A_%H
MVFR%O-O5U>*<Q?*2/D R<G _&L#QM(L'[2GPY:0[%DL+^-2>A;8>*SY(MV\G
MUN=*KU(P4F[^\E\+CNTNK\ST;QGXUTKP%HC:MK$SP62R)$7CC+G<YPO YZUF
M>//BMH'PX>R76I+I#>!FB^SVLDV0N,YV@X^\.M<5^U:0WPI\D']Y/J5I'&O=
MF\S.!^ ->Q*,(!]*FR45)^9NYU)U)TXM*R72^][]5V/)[#]J+P'J4\<5M>7\
MKO((AC3IL!B<8)V\=:[[4/&FDZ9XITOP[<7#)JNIQR26T(C8AU09;Y@,# '>
MO-OV7O\ D5O%7_8RWO\ [)1XZ_Y.6^&O_7E?_P#HLUHX1YW%=+G+3KUO8QJS
M:?,XK:V[L^IZ+XT\>Z%\/M,6^UW4([&&1O+B4@M)*W]U$4$L?H*Q?!OQJ\*>
M.-6;2K&]EM]5"[Q97]N]O*Z^JAP-WX<UR21PZU^U)<1:L%E_LO0DFTJ&7&U6
M=QYDBC^]U&?0>U>IZCX8TG5]5T[4KRP@N;_3V9K6XD7+PDC!VFH:C%6>YT0G
M6JR;@TDG:W73?6^GEH9?C;XF^&OAW';G7M32SDN,^3 J-++)CKM1 21[XQ5?
MPO\ %[P?XQMI9M,UZU?R2%ECG8P2(3G&4?!'0]NU<5\1_!_C'1_B=:^//"=C
M8Z^ZZ=_9TVEWDGENJ[RVZ)CP"?KGKP<\4-._:"\)6VI7T/C3P[)X/\1((Q-#
M>VRRM,O.TK(%RP'/4=^,U2IIQO'7^NQA+%2A5<:C45TNGKY\U[?(O_M,?\@_
MP+_V--E_[-7L;_ZMOQHHJ)?!'YF]+_>*O_;OY'D/[*R"/X1P <_Z==]?^NII
MOP>0+\7/BV1GF_M?_1;445K+>I_75''1_AX;^OLL^:O$_P :O%7PN^*/CVU\
M/W<%O#=:S/+*);=)"6#$#EAQQ7O_ ,#_ (DZY\3_ (.>*M2U^>*XNX7N;=&B
MB6,;!;JV,#W8T45U5HKD3MKH>/@:M1XF4')V][2^A)\(?#=AXO\ V6-.TG4X
MO.M+BRN0PSRI$LC*RGL00"/<5RC^.=7U7]CB6]N+G=>,HTQI_P")H?.$7)[L
M4X)HHK%:R?\ B.V3Y:46O^?3_)'OFC>#M(@\'6>C+8PFP6Q2UV,@),>P*<G'
M4CO7AOA&\FG_ &2/%5K+(TL>GP7]G"S_ 'O+4G:">^,X^F***SAJGZH[,0E%
MJW\DOT/9?@[S\*?"&<G_ (E5M_Z+%<%^U]<R67PA:XB($L6HVSJ2,\AB1114
MT_XR]32O_N#_ ,/Z'@OA']JOXAZMXKT6QN=1M&M[F]AAE4648)5I ",XXX-?
M3/Q_\,VVJ>"VUL2SV>L:"_VW3[VU<+)$^0".005/&1CL***Z:D5&I&RL>1A*
MDZN%K.I)NW?4\4^!?B;5_C_XUM9?&>H2:A!H3"\M;.)$B@:9?NNZJOS$9]?T
MSGZY/2BBL<2DII(]'*).=!SD[MO<\:_9>_Y%?Q5_V,M[_P"R4>.O^3EOAK_U
MY7__ *+-%%#_ (LO1_D$?]SI>L?_ $I$W[17AJ!?#T7C&SN+G3?$>AC-I?6;
MA6VL>4?((9?8^I]3GS/]G?Q%K?QK\6PZOXKUJ\NY-$!FM+6W98(-_"[F5%&[
M@]S^G%%%;4TG1;ZG!B9-9C&">CM=='ZFU^T_XI\0?##6K'Q'X>UZ^M9[J)8)
M;*1DDM2JDX(C93@_,><UR7PC\)6W[2/]K>(_'-S<W^HP&*VA\@I%''&-YVJH
97UYHHK2*2I*2W.6K)SQTJ4G>-WITV['_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>ganx-20230512.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 8:35:08 PM-->
<!--Modified on: 5/11/2023 8:35:08 PM-->
<xsd:schema targetNamespace="http://www.gaintherapeutics.com/20230512" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ganx="http://www.gaintherapeutics.com/20230512">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20230512_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20230512_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="ganx-20230512_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>ganx-20230512_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 8:35:08 PM-->
<!--Modified on: 5/11/2023 8:35:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="ganx-20230512.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:definitionLink xlink:role="http://www.gaintherapeutics.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>ganx-20230512_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 8:35:08 PM-->
<!--Modified on: 5/11/2023 8:35:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document information [Line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>ganx-20230512_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.5.9 -->
<!--Based on XBRL 2.1-->
<!--Created on: 5/11/2023 8:35:08 PM-->
<!--Modified on: 5/11/2023 8:35:08 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="ganx-20230512.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638194341088872326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_DocumentType_638194341088872326" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638194341088872326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_DocumentPeriodEndDate_638194341088872326" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638194341088872326" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityFileNumber_638194341088872326" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityRegistrantName_638194341088882332" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityIncorporationStateCountryCode_638194341088882332" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityTaxIdentificationNumber_638194341088882332" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressAddressLine1_638194341088882332" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressAddressLine2_638194341088882332" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressCityOrTown_638194341088882332" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressStateOrProvince_638194341088882332" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityAddressPostalZipCode_638194341088882332" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_CityAreaCode_638194341088882332" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_LocalPhoneNumber_638194341088882332" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638194341088882332" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_WrittenCommunications_638194341088882332" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_SolicitingMaterial_638194341088892347" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_PreCommencementTenderOffer_638194341088892347" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_PreCommencementIssuerTenderOffer_638194341088892347" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_Security12bTitle_638194341088892347" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_TradingSymbol_638194341088892347" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_SecurityExchangeName_638194341088892347" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638194341088892347" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityEmergingGrowthCompany_638194341088892347" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638194341088902370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityExTransitionPeriod_638194341088902370" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638194341088902370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_EntityCentralIndexKey_638194341088902370" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638194341088902370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract_1" xlink:to="dei_AmendmentFlag_638194341088902370" order="24" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139685047596592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity information<br></strong></div></th>
<th class="th"><div>May 12, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May 12,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40237<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Gain Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">85-1726310<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">4800 Montgomery Lane<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">Suite 220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bethesda<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">500-1556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GANX<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001819411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>ganx-20230512x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="ganx-20230512.xsd" xlink:type="simple"/>
    <context id="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001819411</identifier>
        </entity>
        <period>
            <startDate>2023-05-12</startDate>
            <endDate>2023-05-12</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_r9b28diRhUCZdrmueyAOSA_2_1">0001819411</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_g2TEygbZiEGq9pmgyYK1JA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_q21PL-xFj0eNBqHKheZsiQ">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_xrLhIzdafkKBoSZi0jeODQ">2023-05-12</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_A7B81zAdWU6R1AZPkb17mA">Gain Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_B4bojGnm5USAYq6Pk1bVDA_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_x6YoD16kUECeyYk2v_xM4g_1_2">001-40237</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_MA4FTymF5E6sOPrRaBTYbg_1_4">85-1726310</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_WrkgAjYpF0Ch0UkVXCkuAg">4800 Montgomery Lane</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_gforBLbCAkudwPIeAdgM3w">Suite 220</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_0EgY526XO0WRUL3LNceJeA">Bethesda</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_PLfEiokbh0ezNVXhGiY7PA">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_YplD6_TT50eeHM5EIdX8Zw">20814</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_2F5DroE9F0yvloXpUrFvhA">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_r9VhBCUAEUmASXM3mUM_1w">500-1556</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_zIOwwPPyfUCkOWxeMsrS4Q">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_3I9ar1BM60q4qOjVGS0Gvw">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_jk2st6kjikKK716_up3kAA">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_0uN6J9KST0izMdjCvtqvCA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_PkMIrn85TkWdzDdiN4I59Q_2_0">Common Stock, $0.0001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Tc_NbWnnL5r-0CWapKyu8YDfQ_2_1">GANX</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_OY2pAh-B9kag5Ar1yOihNw">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_N3OMtQnZP0-zCcDVExMZtw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A"
      id="Narr_eR5MHPZ1Ik-409s2e3V-Tg">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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MKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V,D_'T7!S1JP,Z6PE<A!OZ%>Y7>>9
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M)$WS/(X %F>0IA@"IQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04
M" !&0*Q6EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4    " !&0*Q6!T%-8H$
M  "Q    $               @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4
M Q0    ( $9 K%;6XV=E[0   "L"   1              "  :\   !D;V-0
M<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $9 K%:97)PC$ 8  )PG   3
M          "  <L!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @
M1D"L5I$5(;]_!   X!$  !@              ("!# @  'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $9 K%:?H!OPL0(  .(,   -
M          "  <$,  !X;"]S='EL97,N>&UL4$L! A0#%     @ 1D"L5I>*
MNQS     $P(   L              ( !G0\  %]R96QS+RYR96QS4$L! A0#
M%     @ 1D"L5EZ7R>4_ 0  / (   \              ( !AA   'AL+W=O
M<FMB;V]K+GAM;%!+ 0(4 Q0    ( $9 K%8D'INBK0   /@!   :
M      "  ?(1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0
M   ( $9 K%9ED'F2&0$  ,\#   3              "  =<2  !;0V]N=&5N
B=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "$4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="ganx-20230512x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="ganx-20230512x8k.htm">ganx-20230512x8k.htm</File>
    <File>ganx-20230512.xsd</File>
    <File>ganx-20230512_def.xml</File>
    <File>ganx-20230512_lab.xml</File>
    <File>ganx-20230512_pre.xml</File>
    <File>ganx-20230512xex99d1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ganx-20230512x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "contextCount": 1,
   "dts": {
    "definitionLink": {
     "local": [
      "ganx-20230512_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ganx-20230512x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ganx-20230512_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ganx-20230512_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ganx-20230512.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 25,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 24,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "ganx",
   "nsuri": "http://www.gaintherapeutics.com/20230512",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20230512x8k.htm",
      "contextRef": "Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ganx-20230512x8k.htm",
      "contextRef": "Duration_5_12_2023_To_5_12_2023_HUOckdcVj0GQdly8u0dE5A",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Adress Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.gaintherapeutics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001558370-23-009508-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-009508-xbrl.zip
M4$L#!!0    ( $9 K%9SY(A0RP,  !$/   1    9V%N>"TR,#(S,#4Q,BYX
M<V3E5VUOVS80_CY@_X'U=[T:+FHC2=$T&U @V8:T _)MH"E:)B:1&DG5SK_O
MD1(E4Y84I^B  ?MDF??<<V^\.^GJ_;$LT%<J%1/\>I&$\0)13D3&>'Z]J%6
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M)X3D0][L:3S6OI=6BBT&;W^3"D"STE(0#PA\+)#"V@FVO"$UA\2]?C3[<;Q
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MY#HP;[[LZ([M@R@*_LP%U$577W9\,O53(?ND#@]\T[?(X4$J_AW.I3G&[/#
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M?6<<S9-6Q7SZWTE)B%8LRJ(:3I3P^A,K.#!KWW(F44 YOQ8FP(]%C1(\$B:
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M1 E>XAOE1#VF3J5P(LUN+.>7VZ4G-\.G"5):DI\I0Y]?7HC.'7!=FT/'7LA
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MRI2!:+_[^)0_<(,U_(2L8Y(@I1!)N_1]$<8\#)FRFE3\E-S,X"KI0YWLH34
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M$)/4\O!5'OY03XN!C0"=2>8)50!B( 1^XY!MI#AK)SC$JCED+3RIB\ XDKN
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M.?P81Q/O_?\'4$L! A0#%     @ 1D"L5G/DB%#+ P  $0\  !$
M     ( !     &=A;G@M,C R,S U,3(N>'-D4$L! A0#%     @ 1D"L5I)
M=VCE @  '@L  !4              ( !^@,  &=A;G@M,C R,S U,3)?9&5F
M+GAM;%!+ 0(4 Q0    ( $9 K%:6@4H6\@4  $Y&   5              "
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:+FAT;5!+!08     !@ & ) !   _40     !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
